This is strongly supported by a recent study showing that tumor-derived TGF-β could suppress the anti-tumor function of CD4+ T cells through SMAD protein phosphorylation in the tumor effusion fluids of metastatic patients (22). This evidence concerns the gene TGFB1 and neoplasm.